Experimental enzyme inhibitor
 ;templatestyles src="Infobox drug/styles.css"/ ;
}}|[[Category:Infobox drug articles with contradicting parameter input| ]]}}{{#if:|{{#if:
 [[Oral administration|Oral]]
 [[Lysine-specific demethylase 1]] (LSD1) [[enzyme inhibitor|inhibitor]]; [[Monoamine oxidase B]] (MAO-B) [[monoamine oxidase inhibitor|inhibitor]]
}}{{#ifeq:|changed|[[Category:Drugboxes which contain changes to watched fields]]
Vafidemstat ([[International Nonproprietary Name|INN]]Tooltip International Nonproprietary Name; developmental code name ORY-2001) is a dual [[enzyme inhibitor|inhibitor]] of the [[enzyme]]s [[lysine-specific demethylase 1]] (LSD1; KDM1A) and [[monoamine oxidase B]] (MAO-B) which is under development for the treatment of a variety of [[medical condition]]s, including [[aggression]], [[Alzheimer's disease]], [[borderline personality disorder]], [[multiple sclerosis]], [[acute respiratory distress syndrome|acute respiratory disease]] in [[COVID-19]] infection, and [[schizophrenia]]. It is or was also being developed for several other indications, but no recent development has been reported for these uses. The drug is taken [[oral administration|by mouth]].
As of October 2024, vafidemstat is in [[Phases of clinical research#Phase II|phase 2]] [[clinical trial]]s for aggression, Alzheimer's disease, borderline personality disorder, multiple sclerosis, COVID-19 acute respiratory disease, and schizophrenia. Conversely, no recent development has been reported for [[autism]], [[dementia]], [[Huntington's disease]], [[Parkinson's disease]], and [[22q13 deletion syndrome|telomeric 22q13 monosomy syndrome]]. It is being developed by Oryzon.
Other LSD1 inhibitors that are under development for medical use include [[bomedemstat]] (IMG-7289), [[iadademstat]] (ORY-1001), [[phenelzine]] (Nardil), [[pulrodemstat]] (CC-90011), [[seclidemstat]] (SP-2577), and [[tranylcypromine]] (Parnate). Another drug, [[zavondemstat]] (QC8222, TACH101), is a pan-inhibitor of [[KDM4A|lysine-specific demethylase 4]] (LSD4; KDM4). Vafidemstat contains the [[chemical structure]] of (1"S",2"R")-tranylcypromine within its own structure.
References.
 ;templatestyles src="Reflist/styles.css" / ;
[[Category:Amines]]
[[Category:Enzyme inhibitors]]
[[Category:Experimental drugs]]
[[Category:Experimental drugs developed for schizophrenia]]
[[Category:Experimental drugs for Alzheimer's disease]]
[[Category:Experimental psychiatric drugs]]
[[Category:Monoamine oxidase inhibitors]]
[[Category:Oxadiazoles]]
[[Category:Cyclopropanes]]